Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism SARS-CoV 3CLpro inhibitors(SARS-CoV-2-3C-like-proteinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC25H26Cl2N4O3 |
InChIKeyLBLGMVCPRZTJIF-UHFFFAOYSA-N |
CAS Registry2917528-98-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Preclinical | CN | 29 Jul 2024 |